arrow
M

Masaru Harada

University of Occupational and Environmental Health
H指数:37
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

durvalumab联合tremelimumab治疗肝细胞癌患者淋巴细胞计数早期变化可预测临床结局

2026-10-070
OAAI
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study

代谢相关脂肪性肝病与度伐利尤单抗和特瑞普利单抗在晚期肝细胞癌患者临床结局中的关联:一项多中心研究

2025-08-210
PRE
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria

仑伐替尼联合经导管动脉化疗栓塞与阿替利珠单抗联合贝伐珠单抗作为超出“七限”标准的中间期肝细胞癌的一线治疗比较分析

2025-05-310
PRE
Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab

早期外周血淋巴细胞计数升高在预测接受度鲁瓦姆联合特瑞普利单抗治疗晚期肝细胞癌患者临床结局中的价值

CANCERS
IF4.4
2025-04-090
OA
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study

老年丙型肝炎病毒患者持续病毒学应答后的代谢管理: 一项多中心研究

2023-11-2817
PRE
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
2022-10-2231
OAAI
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019
2022-01-2726
OAAI